Tetrahydrocannabiphorol
Viewing r1 — May 11, 2026
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
THCP (Δ9-tetrahydrocannabiphorol) is a naturally-occurring cannabinoid of the dibenzopyran class. It is a structural relative of Δ9-THC, distinguished by a longer alkyl side chain that confers dramatically greater receptor potency. THCP is a full agonist at the CB1, producing its effects by activating endocannabinoid signaling with approximately 33-fold the binding affinity of THC.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Δ9-THC, Δ8-THC, HHC +2 moreΔ9-THC, Δ8-THC, HHC, HHCP, synthetic cannabinoids show less
THCP was first isolated in 2019 from an Italian medicinal cannabis variety by Citti, Linciano, Cannazza, and colleagues.[1] No clinical studies followed — instead, synthetically produced THCP entered commercial vape cartridges and edibles by 2022.[2] It circulates in unregulated cannabinoid markets across Europe and North America, often as a replacement for previously scheduled compounds.[3]
Subjective effects include intense sedation, pronounced euphoria, cognitive impairment, appetite stimulation, and altered time perception. The experience resembles a dramatically amplified cannabis high — qualitatively similar to THC but heavier and more overwhelming, capable of escalating beyond the bounds of typical cannabis intoxication.[3] Anxiety, paranoia, and marked short-term memory loss are common unsought effects.
No dependence data specific to THCP exist, but its full agonist profile — shared with synthetic cannabinoids linked to seizures and loss of consciousness — predicts elevated risk relative to THC.[4] Full agonism removes the efficacy ceiling that THC's partial agonism imposes,[5] and tolerance develops through CB1 receptor desensitization.[6] THCP is among the least-studied cannabinoids available to consumers — no controlled human data, no toxicity characterization, and no established safe dose exist.
History[edit]
History
Discovery
(-)-trans-Δ9-Tetrahydrocannabiphorol was first reported in December 2019 by Cinzia Citti, Pasquale Linciano, Giuseppe Cannazza, and colleagues at the Universities of Modena and Salento in Italy.[1] The compound was isolated from the FM2 medicinal cannabis variety — an Italian military-grown strain — during a systematic profiling of the plant's phytocannabinoid composition using high-resolution mass spectrometry. Its identity was confirmed by co-elution with a synthetic standard prepared from (-)-CBD, and a related compound, cannabidiphorol (CBDP), was co-isolated at the same time.[1]
Scientific significance
The relationship between alkyl side-chain length and CB1 potency had been established decades earlier through synthetic cannabinoid research, where compounds bearing seven- to nine-carbon chains were identified as among the most potent CB1 ligands known.[4] THCP's natural isolation demonstrated that the cannabis plant itself produces a phytocannabinoid reaching this level of potency — a finding that reframed assumptions about the potency ceiling of plant-derived cannabinoids. By 2025, trichome-level analysis of the FM2 variety had catalogued nearly 70 distinct phytocannabinoids, including trace quantities of THCP.[7]
Market emergence
By 2022–2023, THCP-containing vape cartridges and edibles were commercially available in Europe and North America, produced entirely by chemical synthesis rather than natural extraction.[3][2] Market dynamics were shaped by scheduling actions against related compounds — in Sweden, THCP appeared as an unregulated replacement after HHC and HHC-P were classified as narcotics in July 2023.[8] The compound's trajectory from scientific curiosity to commercial product within three years, without intervening safety characterization, typifies the novel psychoactive substance lifecycle in the post-Farm Bill cannabinoid market.[9]
The suffix "phorol" in THCP's name derives from the heptyl (seven-carbon) side chain, following a naming convention where cannabinoid homologs are identified by their alkyl chain length. THCP belongs to a broader family of phorol cannabinoids including CBDP, CBGP, and the hydrogenated structural analog HHCP.
Chemistry[edit]
Chemistry
Structure and classification
THCP belongs to the dibenzopyran terpenoid family, sharing the classical tricyclic cannabinoid scaffold with Δ9-THC, Δ8-THC, and related compounds. Its molecular framework consists of a cyclohexene ring fused to a dihydropyran ring and a phenol-bearing aromatic ring, with a phenolic hydroxyl group serving as the primary hydrogen bond site.
The defining structural feature is a heptyl (seven-carbon) alkyl side chain at the C-3 position, in place of THC's pentyl (five-carbon) chain. This two-carbon extension is the sole structural difference between THCP and THC and is responsible for THCP's dramatically enhanced CB1 affinity.[1]
| Molecular formula | C₂₃H₃₄O₂ |
| Molecular weight | 342.5 g/mol |
Structure-activity relationships
The relationship between alkyl side-chain length and CB1 potency is well-characterized in cannabinoid chemistry: binding affinity increases with chain length up to approximately seven to nine carbons, then plateaus or decreases.[4] THCP sits at the potency peak of this curve. Its structural siblings in the phorol series include cannabidiphorol (CBDP), cannabigerophorol (CBGP), and the hydrogenated structural analog hexahydrocannabiphorol (HHCP).
Stereochemistry
THCP possesses two chirality centers, giving rise to four possible stereoisomers. The naturally occurring form is the (-)-trans enantiomer — the (6aR,10aR) configuration — confirmed by stereoselective synthesis from (-)-CBD and co-elution with the natural isolate.[1] Chiral analysis of the FM2 cannabis variety found no (+) enantiomers for any phytocannabinoids examined.[10] Commercial products may contain Δ8-THCP isomers as synthesis byproducts, the pharmacological activity of which has not been independently characterized.[2]
Biosynthesis
In Cannabis sativa, THCP is produced as a minor phytocannabinoid in trace quantities. The presumed biosynthetic pathway parallels THC biosynthesis but uses a seven-carbon resorcinolic acid precursor rather than the five-carbon olivetolic acid, ultimately yielding a carboxylated precursor (THCPA) that decarboxylates to THCP upon heating. This pathway has not been experimentally confirmed for THCP specifically.[11]
Pharmacology[edit]
Pharmacology
Mechanism of action
THCP activates the CB1 cannabinoid receptor as a full agonist — a critical distinction from Δ9-THC, which acts as a partial agonist at the same target.[5] Full agonism means THCP can drive CB1 signaling to its maximum possible level, whereas THC's partial agonism imposes an intrinsic ceiling on receptor activation regardless of dose.
CB1 activation by THCP triggers the standard inhibitory signaling cascade: reduced cellular excitability, altered ion channel function, and activation of growth-related signaling pathways.[5][4] THCP also binds the CB2 with high affinity, which may contribute anti-inflammatory effects, though no THCP-specific CB2 functional data have been published.[1]
In vivo effects
The standard cannabinoid test battery in mice demonstrated all four classic effects — reduced movement, pain suppression, immobility, and lowered body temperature — at doses where Δ9-THC was inactive or less effective.[1] These results confirm that THCP's enhanced binding affinity translates to greater potency in living organisms.
All potency data are from mice only; no primate or human dose-response data exist.safety citation needed
Pharmacokinetics
No human pharmacokinetic studies for THCP have been published. The following is inferred from structural similarity to Δ9-THC and the related compound HHCP.
THCP is highly fat-soluble and is expected to absorb rapidly when inhaled and more slowly when swallowed, with significant first-pass liver metabolism reducing oral availability.inferred The longer side chain predicts greater fat solubility than THC, likely resulting in extensive accumulation in body fat and a prolonged elimination time.inferred
Metabolism is expected to follow THC's primary route — liver enzymes oxidizing the molecule at multiple positions.[12] The longer heptyl chain provides additional sites for enzymatic modification, resulting in a more complex metabolite profile than THC. Studies of the related compound HHCP in human liver cells found that the vast majority of metabolites were present as conjugated forms ready for excretion.[13][14]
All pharmacokinetic statements for THCP are structural analog inferences, not substance-specific data.
Neuroscience[edit]
Neuroscience
Where it acts
No neuroimaging or electrophysiology studies specific to THCP have been published. By mechanism, THCP acts on CB1 receptors — the most abundant receptor of their type in the brain — concentrated in the hippocampus (memory), basal ganglia (movement), cerebellum (coordination), and prefrontal cortex (judgment and planning). CB1 activation suppresses neurotransmitter release from nerve terminals, dampening both excitatory and inhibitory signaling depending on the circuit.
The hippocampal CB1 population mediates the short-term memory suppression characteristic of cannabinoid intoxication, and THCP's substantially higher CB1 affinity predicts more profound memory disruption at lower doses.inferred Amygdala CB1 receptors produce dose-dependent effects on anxiety: low-level activation reduces it, while high-level activation provokes it — consistent with user reports of dose-dependent transitions from calm to paranoia.[3]
Why it matters
The endocannabinoid system functions as a demand-driven regulator of brain activity, fine-tuning signaling strength in response to moment-to-moment neural needs. THCP, like all exogenous cannabinoids, overrides this precision by providing continuous, non-demand-driven CB1 activation. Over time, the brain compensates through downregulation and desensitization — the mechanism underlying tolerance.[6]
THCP's full agonism may also produce greater activation of the brain's mesolimbic pathway than THC. CB1 receptors on inhibitory neurons in the reward circuit release a brake on dopamine signaling; full agonism releases this brake more completely than partial agonism, potentially contributing to stronger reinforcement and elevated dependence risk.inferred
- Does THCP cross the blood-brain barrier more readily than THC? Greater fat solubility generally enhances brain penetration, but the relationship is complex and THCP-specific data are absent.
- What are the neurocognitive consequences of chronic THCP use? High-potency cannabis is associated with reduced hippocampal volume and altered brain connectivity — whether THCP's higher potency amplifies these effects is unknown.
- Does THCP affect the developing brain differently from THC? Adolescent exposure to potent CB1 agonists disrupts normal brain maturation processes,[15] and the developmental toxicity threshold for THCP has not been investigated.
Subjective Effects[edit]
Subjective Effects
The THCP experience represents a qualitative shift from familiar cannabis intoxication rather than a simple intensification. Full CB1 agonism removes the efficacy ceiling that Δ9-THC's partial agonism imposes, meaning the experience can escalate — particularly at higher doses or through impatient redosing of oral preparations — into territory where cognitive function, motor control, and emotional stability are substantially compromised. Set and setting retain modulatory influence, but the narrow margin between desired effects and overwhelming intoxication makes environmental and psychological preparation less protective than with THC.[3]
Within the cannabinoid class, THCP sits pharmacologically closer to synthetic cannabinoids like JWH-018 and CP55940 than to Δ9-THC, despite its natural phytocannabinoid origin. Consumer reports describe effects that can exceed the bounds of typical cannabis experience — particularly in sedation depth and cognitive disruption — placing THCP in an intermediate zone between traditional cannabis and the synthetic cannabinoid class.[3]
Effect Grid
Pronounced euphoria and sedation define the common-dose experience. Cognitive impairment becomes clear — short-term memory is disrupted, focus is suppressed, and thought tempo decelerates noticeably. Time distortion is prominent, with minutes feeling substantially elongated. Appetite enhancement is strong. Emotional responses are heightened, and humor enhancement is typical.
Body heaviness and muscle relaxation are substantial. Dry mouth is likely. Heart rate perception changes may be noticed. Motor control is meaningfully impaired — coordination tasks become clumsy. A warm, spreading body high pervades.
Anxiety is possible in predisposed individuals or unfamiliar settings. Functional impairment is significant — driving and complex tasks are unsafe. Duration of commitment is several hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Proprioceptive distortion · Sound sensitivity · Spatial disorientation · Touch enhancement · Taste enhancement · Peripheral vision distortion · Auditory distortion · Color alteration · Visual acuity suppression · Visual haze / noise · Peripheral misidentification · Auditory misinterpretation · Light sensitivity · Vestibular distortion · Visual breathing · Olfactory enhancement · After-images · Tracers · Visual drifting
Touch enhancement · Taste enhancement · Peripheral vision distortion · Auditory distortion · Color alteration · Visual acuity suppression · Visual haze / noise · Peripheral misidentification · Auditory misinterpretation · Light sensitivity · Vestibular distortion · Visual breathing · Olfactory enhancement · After-images · Tracers · Visual drifting
Bodily heaviness · Heart rate perception changes · Muscle relaxation · Pain suppression · Appetite enhancement · Dehydration sensation · Dizziness · Laughter fits · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Temperature dysregulation · Body schema distortion · Nausea suppression · Pupil dilation · Breathing alteration · Constipation · Headache · Insomnia · Nausea · Nystagmus (eye wobbles) · Sexual arousal enhancement · Sexual arousal suppression · Muscle tension · Restlessness · Stimulation · Tingling / electric sensations · Trembling · Vibrations / buzzing · Vomiting · Bodily dissociation
Pain suppression · Appetite enhancement · Dehydration sensation · Dizziness · Laughter fits · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Body schema distortion · Nausea suppression · Pupil dilation · Breathing alteration · Constipation · Headache · Insomnia · Nausea · Nystagmus (eye wobbles) · Sexual arousal enhancement · Sexual arousal suppression · Muscle tension · Restlessness · Stimulation · Tingling / electric sensations · Trembling · Vibrations / buzzing · Vomiting · Bodily dissociation
Memory fragmentation · Memory suppression · Aesthetic enhancement · Analysis suppression · Cognitive euphoria · Confusion · Immersion enhancement · Information processing suppression · Introspection enhancement · Novelty enhancement · Openness enhancement · Thought connectivity · Thought disorganization · Humor enhancement · Motivation suppression · Cognitive dysphoria · Conceptual thinking · Creativity enhancement · Increased nature relatedness · Language suppression · Multiple thought streams · Pattern recognition enhancement · Suggestibility enhancement · Thought deceleration · Thought loops · Compulsive redosing urge · Creativity suppression · Amnesia · Delirium · Delusions
Analysis suppression · Cognitive euphoria · Confusion · Immersion enhancement · Information processing suppression · Introspection enhancement · Novelty enhancement · Openness enhancement · Thought connectivity · Thought disorganization · Humor enhancement · Motivation suppression · Cognitive dysphoria · Conceptual thinking · Creativity enhancement · Increased nature relatedness · Language suppression · Multiple thought streams · Pattern recognition enhancement · Thought deceleration · Thought loops · Compulsive redosing urge · Creativity suppression · Amnesia · Delirium · Delusions
Anxiety suppression · Emotional lability · Dysphoria · Emotional suppression · Empathy enhancement · Irritability · Simultaneous emotions · Anhedonia · Empathy suppression · Mania
Emotional suppression · Empathy enhancement · Irritability · Simultaneous emotions · Anhedonia · Empathy suppression
Depersonalization · Derealization · Sociability enhancement · Compulsive behavior reduction · Sociability suppression · Social connection · Social disconnection · Trust enhancement · Communication enhancement · Flow state · Ego inflation · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Sociability suppression · Social connection · Social disconnection · Trust enhancement · Communication enhancement · Flow state · Ego inflation · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Timeline
Delayed onset typical of oral cannabinoids. A subtle shift in mood or body awareness emerges 30–90 minutes after ingestion. The slow onset increases redosing risk.
Gradual intensification over 30–60 minutes. Euphoria, body warmth, and cognitive slowing build steadily. First-pass metabolism may produce an active 11-OH metabolite contributing to intensity.
Full intoxication — potentially more intense than the vaporized route due to 11-OH metabolite contribution. Sedation, cognitive impairment, and time distortion reach maximum. Anxiety risk elevated.
Extended plateau characteristic of oral cannabinoid administration. Effects remain strong and sustained. Body heaviness and appetite stimulation persist at near-peak levels.
Slow decline over several hours. Sedation and cognitive fog recede gradually. Motor coordination returns but may remain subtly impaired.
Prolonged residual effects including mild sedation, cognitive haze, and appetite changes. Next-day grogginess is possible, particularly at higher doses.
⚠ Do not drive or operate heavy machinery for at least 12 hours after oral ingestion, or longer if any impairment is perceived.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 3 weeks
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- Δ9-THC · Δ8-THC · HHC
Toxicity
No LD50 data for THCP have been published in any species, and no therapeutic index can be estimated. Acute lethal toxicity is expected to be low in absolute terms by analogy with Δ9-THC, but the dose at which severe adverse effects occur is much lower than for THC due to THCP's greater potency and full agonist profile.safety citation needed
Acute toxicity
The primary acute risks are neuropsychiatric. Full CB1 agonists with potency comparable to THCP — including synthetic cannabinoids of the JWH and HU series — have been associated with seizures, loss of consciousness, and coma.[4] Rapid heart rate is a class effect of CB1 agonism; at high doses or in predisposed individuals, heart rhythm disturbances are possible. No THCP-specific case reports documenting these outcomes have been published.
Product contamination
Commercial THCP products pose risks beyond the active compound itself. Laboratory analysis of a commercial THCP vape cartridge revealed unlabeled synthetic impurities including olivetol structural analog precursors, bisalkylated compounds, and Δ8-THCP isomers.[2] The toxicity of these byproducts is unknown, and product labels may not accurately reflect THCP content.[2]
Psychological Risks
Acute cannabis-associated psychotic symptoms — including hallucinations, paranoia, and thought disorganization — occur in approximately 0.47% of cannabis users over a lifetime, with substantially elevated risk in young users, users of high-potency preparations, and individuals with pre-existing psychiatric vulnerability.[16] THCP's markedly higher potency suggests a lower threshold for these effects and amplified risk at equivalent product doses.
High-potency cannabis is specifically associated with poorer mental health outcomes in adolescents, including increased rates of anxiety disorders, depression, and psychotic experiences.[15] THCP's exceptional potency places it at the extreme end of this risk spectrum. No THCP-specific data on persisting perceptual changes, depersonalization, or long-term psychiatric outcomes have been published.
Tolerance & Dependence
No THCP-specific tolerance or dependence data exist. Chronic CB1 agonist exposure produces receptor desensitization and downregulation, resulting in behavioral tolerance.[6] THCP's higher intrinsic efficacy as a full agonist may drive tolerance development more rapidly and completely than THC — a pattern observed with synthetic cannabinoids of comparable potency.inferred
Cross-tolerance between THCP and Δ9-THC is highly likely given their shared CB1 target but has not been experimentally confirmed. Cannabis use disorder develops in approximately 9% of cannabis users overall and up to 17% of those initiating use in adolescence.citation needed THCP's higher potency and full agonism predict elevated abuse liability relative to THC.
Cannabis withdrawal is characterized by irritability, anxiety, sleep disturbance, decreased appetite, and low mood, beginning 1–3 days after cessation and peaking around days 2–6. No pharmacotherapy is currently approved for cannabis withdrawal.[17] THCP-specific withdrawal has not been characterized.
Drug Interactions
No THCP-specific drug interaction studies have been published. All interaction data are inferred from Δ9-THC pharmacology.[12][18]
THCP is expected to be processed by the same liver enzymes as THC and may inhibit them. Co-administration with warfarin carries a risk of increased bleeding. Immunosuppressants (tacrolimus, cyclosporine) may reach dangerous levels. Antiseizure medications (valproate, clobazam) face both enzyme inhibition and additive sedation.
Co-administration with alcohol, benzodiazepines, or opioids produces additive sedation and respiratory depression. The opioid interaction carries particular risk given receptor crosstalk that may mask breathing problems. Chronic cannabinoid use is associated with increased anesthetic requirements[6] — patients using THCP should disclose this to anesthesia providers.
All interaction severities are uncharacterized for THCP specifically.safety citation needed
Contraindications
No THCP-specific contraindication data exist. The following are inferred from full CB1 agonist pharmacology.
Absolute contraindications:
- Personal or family history of psychotic disorders — CB1 agonism precipitates and worsens psychotic symptoms; full agonism at THCP's potency amplifies this risk[16]
- Unstable heart conditions — rapid heart rate and blood pressure effects of potent CB1 agonism pose risk in the context of rhythm disorders, recent heart attack, or heart failuresafety citation needed
Relative contraindications:
- Bipolar disorder — CB1 agonism may trigger manic episodes
- Pregnancy and breastfeeding — cannabinoids cross the placenta and enter breast milk; high-potency CB1 agonism poses unknown developmental risk
- Adolescence — developing endocannabinoid systems are vulnerable to disruption by potent exogenous agonists[15]
- Medications with narrow safety margins processed by CYP2C9 or CYP3A4 (warfarin, tacrolimus, cyclosporine)[18]
- History of cannabis use disorder — full agonism and higher potency predict stronger reinforcement
- Liver impairment — reduced metabolism may increase THCP exposure and prolong effectsinferred
All contraindications are class-level inferences.
Harm Reduction[edit]
Harm Reduction
Forms & Identification
Commercial THCP is produced entirely by chemical synthesis, not by extraction from cannabis plants. Every product's safety profile depends on the quality of the synthesis and purification process. Laboratory analysis has confirmed that commercial products may contain unlabeled impurities whose toxicity is unknown[2] — standard cannabis reagent testing is insufficient to identify these contaminants.
The absence of standardized production means labeled potency may not reflect actual THCP content. Treating every new product or batch as an unknown potency is the most conservative approach.
Set & Setting
THCP's high potency and full agonist profile create a narrow margin between desired effects and overwhelming intoxication. A calm, familiar, private environment with a sober companion present significantly reduces the risk of anxiety escalation, paranoia, and disorientation — especially for those without prior experience with the compound.
Avoid using THCP in unfamiliar, public, or socially demanding settings. The cognitive impairment and heavy sedation reported at even moderate doses can make navigation, communication, and self-care difficult.
Guidelines
- Test every product. Third-party laboratory certificates of analysis (COAs) are the minimum standard — products without them should be treated as unverified.
- Start with the lowest available dose and wait. Oral THCP has delayed and variable onset; redosing before full effects manifest is the most common path to accidental overdose with potent edibles.
- Inhaled THCP allows better dose control than oral preparations, but onset is rapid and the window between desired effect and overwhelming intoxication is narrow.
- Do not use alone until the individual response is well established. A sober companion should be present for first experiences.
- Do not drive or operate machinery. THCP produces substantial cognitive and motor impairment.
- Keep sessions infrequent. Full CB1 agonism predicts faster tolerance development and potentially greater abuse liability than THC.
Aftercare & Integration
THCP's potency can produce experiences that feel qualitatively different from ordinary cannabis use — intense sedation, pronounced cognitive disruption, and anxiety or paranoia that may linger after the acute effects resolve. Allow a full recovery day after use, prioritizing sleep, hydration, and light nutrition.
If the experience produced significant anxiety, paranoia, or depersonalization, processing with a trusted person can help contextualize what happened. Persistent anxiety, mood changes, or perceptual disturbances lasting more than a few days warrant consultation with a mental health professional. Journaling the experience — dose, setting, timeline, and effects — builds a personal reference that supports safer future decisions.
Recovery & Support
THCP's full CB1 agonism and high potency predict elevated dependence risk relative to conventional cannabis. Signs of problematic use include escalating doses, difficulty controlling frequency, continued use despite negative consequences, and withdrawal symptoms (irritability, anxiety, sleep disruption, appetite suppression) upon cessation.
Cannabis use disorder is a recognized clinical condition with effective treatment options including cognitive behavioral therapy, motivational enhancement therapy, and contingency management. No pharmacotherapy is currently approved for cannabis withdrawal, but clinical support can substantially ease the process. Resources include the SAMHSA National Helpline (1-800-662-4357), Marijuana Anonymous (marijuana-anonymous.org), and local addiction medicine providers.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable but manageable effects include anxiety, rapid heartbeat, nausea, and disorientation. Seek immediate help if any of the following occur: seizure activity, loss of consciousness or unresponsiveness, chest pain, severe breathing difficulty, or psychotic symptoms (complete disconnection from reality, self-harm risk, extreme agitation unresponsive to reassurance).
Immediate steps:
- 1. Call emergency services if the person is unconscious, seizing, or showing signs of psychosis with self-harm risk.
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- 3. Do not leave the person alone. Speak calmly and reassuringly.
- 4. Do not restrain unless there is immediate danger of self-harm or harm to others.
- 5. Do not induce vomiting.
- 6. Remove stimulating inputs — lower lights, reduce noise.
What to tell the dispatcher: State the substance (THCP, a potent cannabinoid), the approximate amount and time consumed, the route (inhaled or oral), and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution when seeking medical help for drug-related emergencies.
No reversal agent exists for cannabinoid intoxication. Treatment is supportive.
Legal Status[edit]
Legal Status
THCP occupies an evolving and jurisdiction-dependent legal position. As a naturally occurring phytocannabinoid first characterized in 2019, it was not named in any existing controlled substance schedules at the time of its discovery. Its rapid commercialization — primarily as a synthetically produced product — has prompted scheduling actions in multiple jurisdictions, though explicit legal status varies significantly.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Unscheduled; legal gray zone | Potentially legal under the 2018 Farm Bill if derived from hemp with less than 0.3% Δ9-THC by dry weight. Congress revised the Farm Bill definition in November 2025 to encompass total THC (not only Δ9-THC), effective November 2026, which may substantially affect THCP's federal status[19] |
| United States (state-level) | Banned in multiple states | As of mid-2025, Alaska, Delaware, Hawaii, Idaho, Mississippi, Montana, New York, North Dakota, Rhode Island, Vermont, Washington, and West Virginia have enacted bans or analog scheduling covering THCP[19] |
| United Kingdom | Likely Class B (Misuse of Drugs Act 1971) | Controlled under analogue provisions covering psychoactive cannabinoids structurally related to THC. THCP is not explicitly named[20] |
| Sweden | Narcotic | Classified as a narcotic substance effective July 11, 2023[8] |
| Switzerland | Banned | THCP and related dibenzopyran-structure cannabinoids banned October 2023[2] |
| France | Banned | Banned in 2024[20] |
| Czech Republic | Controlled | Added to controlled substances list in early 2024[20] |
| Spain | Schedule II | Added to Schedule II in April 2025[20] |
| Denmark | Not explicitly banned (as of 2024) | HHC scheduling in May 2023 shifted market dynamics but THCP was not explicitly controlled during the study period[21] |
| Canada | Likely controlled (CDSA Schedule II) | THC analogues are controlled under the Controlled Drugs and Substances Act. THCP as a THC homolog is likely controlled, but explicit naming has not been confirmedcitation needed |
| Australia | Likely Schedule 9 (Poisons Standard) | Expected to be controlled as a THC analogue, but THCP has not been found explicitly named in a published scheduling decisioncitation needed |
The scheduling trajectory follows a consistent pattern: THCP enters markets as an unregulated alternative after related compounds are scheduled, prompting reactive regulatory responses within 12–24 months.[8][9] This reactive cycle — commercialization outpacing regulation — is characteristic of the novel psychoactive substance market.
references
- [1] ^abcdefghCitti C, Linciano P, Russo F, Luongo L, Iannotta M, Maione S, Laganà A, Capriotti AL, Forni F, Vandelli MA, Gigli G, Cannazza G (2019) A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol — Scientific Reports doi:10.1038/s41598-019-56785-1
- [2]
- [3]
- [4]
- [5] ^abcJanssens LK, Van Uytfanghe K, Williams JB, Hering KW, Iula DM, Stove CP (2024) Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays - and how this matters for the harm potential of seized drugs — Archives of Toxicology doi:10.1007/s00204-024-03769-4
- [6] ^abcdMann DK, Portnof J, Adlesic E (2026) Marijuana Use and Its Impact on Outpatient Anesthesia. — Anesthesia Progress doi:10.2344/25-0009